Cargando…

The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome

BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute co...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarma, Amy, Cannon, Christopher P., de Lemos, James, Rouleau, Jean L., Lewis, Eldrin F., Guo, Jianping, Mega, Jessica L., Sabatine, Marc S., O'Donoghue, Michelle L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309063/
https://www.ncbi.nlm.nih.gov/pubmed/24786143
http://dx.doi.org/10.1161/JAHA.114.000784
_version_ 1782354629369004032
author Sarma, Amy
Cannon, Christopher P.
de Lemos, James
Rouleau, Jean L.
Lewis, Eldrin F.
Guo, Jianping
Mega, Jessica L.
Sabatine, Marc S.
O'Donoghue, Michelle L.
author_facet Sarma, Amy
Cannon, Christopher P.
de Lemos, James
Rouleau, Jean L.
Lewis, Eldrin F.
Guo, Jianping
Mega, Jessica L.
Sabatine, Marc S.
O'Donoghue, Michelle L.
author_sort Sarma, Amy
collection PubMed
description BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute coronary syndrome (ACS) and randomized them to atorvastatin 80 mg/day versus pravastatin 40 mg/day. A‐to‐Z enrolled 4497 subjects after ACS and randomized them to a high‐potency (simvastatin 40 mg/day×1 months, then simvastatin 80 mg/day) versus a delayed moderate‐potency statin strategy (placebo×4 months, then simvastatin 20 mg/day). Serum creatinine was assessed centrally at serial time points. Adverse events (AEs) relating to kidney injury were identified through database review. Across both trials, mean serum creatinine was similar between treatment arms at baseline and throughout follow‐up. In A‐to‐Z, the incidence of a 1.5‐fold or ≥0.3 mg/dL rise in serum creatinine was 11.4% for subjects randomized to a high‐potency statin regimen versus 12.4% for those on a delayed moderate‐potency regimen (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.76 to 1.10; P=0.33). In PROVE IT‐TIMI 22, the incidence was 9.4% for subjects randomized to atorvastatin 80 mg/day and 10.6% for subjects randomized to pravastatin 40 mg/day (OR, 0.88; 95% CI, 0.71 to 1.09; P=0.25). Consistent results were observed for different kidney injury thresholds and in individuals with diabetes mellitus or with moderate renal dysfunction. The incidence of kidney injury‐related adverse events (AEs) was not statistically different for patients on a high‐potency versus moderate‐potency statin regimen (OR, 1.06; 95% CI, 0.68 to 1.67; P=0.78). CONCLUSIONS: For patients enrolled in 2 large randomized trials of statin therapy after ACS, the use of a high‐potency statin regimen did not increase the risk of kidney injury.
format Online
Article
Text
id pubmed-4309063
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-43090632015-01-28 The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome Sarma, Amy Cannon, Christopher P. de Lemos, James Rouleau, Jean L. Lewis, Eldrin F. Guo, Jianping Mega, Jessica L. Sabatine, Marc S. O'Donoghue, Michelle L. J Am Heart Assoc Original Research BACKGROUND: Observational studies have raised concerns that high‐potency statins increase the risk of acute kidney injury. We therefore examined the incidence of kidney injury across 2 randomized trials of statin therapy. METHODS AND RESULTS: PROVE IT‐TIMI 22 enrolled 4162 subjects after an acute coronary syndrome (ACS) and randomized them to atorvastatin 80 mg/day versus pravastatin 40 mg/day. A‐to‐Z enrolled 4497 subjects after ACS and randomized them to a high‐potency (simvastatin 40 mg/day×1 months, then simvastatin 80 mg/day) versus a delayed moderate‐potency statin strategy (placebo×4 months, then simvastatin 20 mg/day). Serum creatinine was assessed centrally at serial time points. Adverse events (AEs) relating to kidney injury were identified through database review. Across both trials, mean serum creatinine was similar between treatment arms at baseline and throughout follow‐up. In A‐to‐Z, the incidence of a 1.5‐fold or ≥0.3 mg/dL rise in serum creatinine was 11.4% for subjects randomized to a high‐potency statin regimen versus 12.4% for those on a delayed moderate‐potency regimen (odds ratio [OR], 0.91; 95% confidence interval [CI], 0.76 to 1.10; P=0.33). In PROVE IT‐TIMI 22, the incidence was 9.4% for subjects randomized to atorvastatin 80 mg/day and 10.6% for subjects randomized to pravastatin 40 mg/day (OR, 0.88; 95% CI, 0.71 to 1.09; P=0.25). Consistent results were observed for different kidney injury thresholds and in individuals with diabetes mellitus or with moderate renal dysfunction. The incidence of kidney injury‐related adverse events (AEs) was not statistically different for patients on a high‐potency versus moderate‐potency statin regimen (OR, 1.06; 95% CI, 0.68 to 1.67; P=0.78). CONCLUSIONS: For patients enrolled in 2 large randomized trials of statin therapy after ACS, the use of a high‐potency statin regimen did not increase the risk of kidney injury. Blackwell Publishing Ltd 2014-05-01 /pmc/articles/PMC4309063/ /pubmed/24786143 http://dx.doi.org/10.1161/JAHA.114.000784 Text en © 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/3.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research
Sarma, Amy
Cannon, Christopher P.
de Lemos, James
Rouleau, Jean L.
Lewis, Eldrin F.
Guo, Jianping
Mega, Jessica L.
Sabatine, Marc S.
O'Donoghue, Michelle L.
The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title_full The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title_fullStr The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title_full_unstemmed The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title_short The Incidence of Kidney Injury for Patients Treated With a High‐Potency Versus Moderate‐Potency Statin Regimen After an Acute Coronary Syndrome
title_sort incidence of kidney injury for patients treated with a high‐potency versus moderate‐potency statin regimen after an acute coronary syndrome
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309063/
https://www.ncbi.nlm.nih.gov/pubmed/24786143
http://dx.doi.org/10.1161/JAHA.114.000784
work_keys_str_mv AT sarmaamy theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT cannonchristopherp theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT delemosjames theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT rouleaujeanl theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT lewiseldrinf theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT guojianping theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT megajessical theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT sabatinemarcs theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT odonoghuemichellel theincidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT sarmaamy incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT cannonchristopherp incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT delemosjames incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT rouleaujeanl incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT lewiseldrinf incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT guojianping incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT megajessical incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT sabatinemarcs incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome
AT odonoghuemichellel incidenceofkidneyinjuryforpatientstreatedwithahighpotencyversusmoderatepotencystatinregimenafteranacutecoronarysyndrome